Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice
and research. The exponential rise in technology powered by AI is defining new frontiers in …

Randomized clinical trials are the gold standard for establishing the efficacy and safety of
cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and …

Recent advances in neural camera imaging pipelines have demonstrated notable progress.
Nevertheless, the real-world imaging pipeline still faces challenges including the lack of joint …

Artificial intelligence (AI) is already revolutionizing the conduct of science and the practice of
medicine. From basic discovery to gaining insights about someone's health through …

Background Heart failure with preserved ejection fraction (HFpEF) is the predominant form
of HF in older adults. It represents a heterogenous clinical syndrome that is less well …

Artificial intelligence has increasingly become an integral part of our daily activities.
ChatGPT, a natural language processing technology developed by OpenAI, is widely used …

Systematic, standardized, and independent assessment of clinical trial end points is critical
to protect the scientific integrity of clinical trials. 1 Clinical event classification (CEC) has …

Background Efficient data exchange and health care interoperability are impeded by
medical records often being in nonstandardized or unstructured natural language format …

Background: Subject screening is a key aspect of all clinical trials; however, traditionally, it is
a labor-intensive and error-prone task, demanding significant time and resources. With the …

Background: Medical record review by a physician clinical events committee is the gold
standard for identifying cardiovascular outcomes in clinical trials, but is labor-intensive and …